Business wire
- Join Us in January for More Investor and Partnering Meetings and High Profile Panels at Biotech Showcase -
BioFuture™ 2024 Wraps Up: Hundreds of High-Profile Attendees Joined Record Numbers of Investors and Media
Media Contact:
Katie Morris
ENTENTE Network of Companies
katiemorris@ententeinc.com
Demy-Colton’s BioFuture™ conference wrapped up in New York and virtually with the largest turnout in the event’s history. 100+ speakers, 100+ investors, 62 presenting companies and 48 journalists participated in dozens of public, private and seed-stage innovation company presentations, 2,085 one-to-one meeting requests, 440 meetings scheduled and media interviews focused on the future of the life sciences, diagnostics, techbio, pharmaceutical, health delivery and digital health sectors.
BioFuture’s “Big Think” Plenary Sessions, fireside chats and workshops are poised to transform healthcare over the coming decade – from policy to AI and bioelectronics to the evolving funding landscape, among others.
Speakers included:
- Susan Hockfield, Ph.D., former president of MIT
- Kevin Tracey, M.D., President and CEO, Feinstein Institutes for Medical Research at Northwell Health
- Wade Davis, Vice President of Computational Science & Head of Digital for Research, Moderna
- Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Member of the Executive Committee, Ipsen
- Seema Kumar, CEO, Cure
- Daniella Kranjac, Founding General Partner, Avant Bio
- Victoria Lipinska, Americas Lead for Quantum Innovation Centers, IBM
- Congressman Jake Auchincloss, MA-04
- Georgia Ravitz, Partner, FDA & Healthcare Regulatory, Orrick
- Nouhad Husseini, SVP, Head of Business Development and Corporate Strategy, Regeneron Pharmaceuticals
- And members of the media, including Max Bayer of Endpoints News, Hilary Brueck of Business Insider, Uduak Thomas of Genetic Engineering & Biotechnology News and Sony Salzman of ABC News, among others.
“The BioFuture conference in New York featured panels that got into the nitty-gritty of drug development – from using artificial intelligence to improve the efficiency of drug development, to finding investors, and eventual issues with the ability and willingness to pay for them... Panelists offered a range of viewpoints on these and other hot topics,” said Scrip reporter Alaric DeArment in coverage following the event.
HelloPartnering is still open and will remain accessible for 6 months (April 30th). Attendees will be able to contact each other but not schedule meetings. Registered participants can access BioFuture’s on-demand access to company presentations and session recordings by logging into HelloPartnering with their registration details.
“Innovation thrives when visionary leaders and innovators come together,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “The conference’s growth this year is a testament to the value it delivers to participants in understanding the market, policy and other factors that impact the future of their businesses and healthcare. This year’s dialog tackled some of the most complex challenges in medicine and healthcare delivery – from the emergence of techbio to the implementation of the Inflation Reduction Act. Our industry is at an important inflection point, and we look forward to continuing these future leading conversations at Biotech Showcase in January.”
Biotech Showcase is the premier investor conference for private and micro to mid-cap biotechnology companies. It brings together 3,400 attendees – including nearly 1,300 investors and 110 members of the media.
For more information, please visit www.biofuture.com or follow us on X at @DemyColton and #BioFuture2024. For information about Biotech Showcase or to apply to present or sponsor, please visit www.biotech-showcase.com.
About BioFuture
Sponsored by Aisling Capital, Pappas Capital, Regeneron, JP Morgan, BioWorld, Emerald Bioventures, KKH Advisors, BKW, Cure, ENTENTE Network of Companies/ENMEDIA, EntityRisk, IPSEN, Mineralys, NYC Economic Development Corporation, Orrick, and Wilson Sonsini, BioFuture is the premier conference where therapeutic pioneers, innovators, and investors gather to assess and shape the future of healthcare and digital health.
About Demy-Colton
Demy-Colton is a premier life sciences events organization committed to connecting industry leaders and fostering partnerships that advance life sciences innovation globally. Demy-Colton’s portfolio includes Biotech Showcase™, BioFuture™, and the Biotech CEO Summits in Europe and La Jolla, as well as virtual events designed to keep life sciences professionals connected year-round.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241122292461/en/
